SOURCE: IBC Life Sciences

January 23, 2006 09:00 ET

IBC Announces 5th International Preclinical Development Forum

WESTBOROUGH, MA -- (MARKET WIRE) -- January 23, 2006 --IBC announced its 5th International Preclinical Development Forum to be held March 20-22, 2006 at the Hyatt Harborside Hotel in Boston, MA. This event will present proven strategies and methods to conquer the set of challenges imposed on scientists and project teams by the combination of resource constraints and pressure to optimize the speed and output of preclinical development. This will maximize the return on investment in development candidates.

One of the many highlights of this event will include the Keynote Presentation "Improving the Efficiency of Preclinical Development" to be given by Frank L. Douglas, M.D., Ph.D., Executive Director, MIT Center for Biomedical Innovation.

The conference will contain 17 Strategic Case Studies including:

Millennium Pharmaceuticals: How increasing analytical detail can improve understandings of concentration:effect relationships and support more robust toxicology studies

Pfizer: Analysis of seven different pharmacology classes to measure the link between the similarity of preclinical drug-induced effect patterns and whole organism response

Eisai Research Institute, University of Saskatchewan and Elixir Pharmaceuticals: Developments and strategies for animal efficacy models of inflammatory, cardiovascular and metabolic diseases

Abbott Laboratories: Implement and position biomarkers in vitro and in vivo to identify compounds with an acceptable toxicologic profile

Roche: Assess major drug transporters and use this information to eliminate unfavorable properties of potential clinical development candidates.

In addition to the unrivaled content it will also feature two In-Depth Workshops:

Resource Allocation and Project Management in Preclinical Development: Case studies of successful, multi-disciplinary project teams -- and strategies on CRO usage, technology planning and management of preclinical decision gates.

Evaluation, Validation and Application of Preclinical DMPK Assays: Apply early and development stage assay data to prioritize candidates and build intrinsic ADMET quality into molecules.

"This was a well organized conference, where active participation by scientists from academia and industry was enriching. Topics were well covered in adequate depth," noted Chandra Natarajan of Aventis about a previous Preclinical Development Forum held in Cambridge, MA.

ATTENTION CALENDAR EDITORS! For more information on attending Preclinical Development Forum at the Hyatt Harborside Hotel in Boston, MA visit http://www.IBClifesciences.com/pdf

Contact Information